They also evaluated EZH2 levels in nine low-grade gliomas and detected that the secretion of EZH2 was 4.26 ± 2.90-fold elevated compared to normal brains, which was significantly lower than that in GBM [119]. The gene discussed is EZH2; the disease is central nervous system cancer.